Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
CAPS Rating:
Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.
RSS Headlines
Fool UK
Recs
way oversold for the promising potential here